- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07944066
SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis (SAVE-AS)
Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Assess the Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitor in Patients With Aortic Valve Stenosis: SAVE-AS (SGLT2i Assessment Valvular Effect in AS)
Aortic stenosis (AS) is the most common valvular heart disease, and no medical therapy has been shown to slow its progression; treatment is limited to surgical or transcatheter aortic valve replacement once symptoms or left ventricular dysfunction develop. Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular death and heart failure hospitalization in patients with and without diabetes, and preclinical studies show that they suppress the inflammatory (NLRP3 inflammasome), fibrotic (TGF-beta/Smad), and oxidative-stress pathways that drive valve calcification. A recent observational study reported slower AS progression in patients treated with SGLT2 inhibitors.
SAVE-AS is a multicenter, prospective, randomized, double-blind, placebo-controlled, investigator-initiated superiority trial testing whether the SGLT2 inhibitor enavogliflozin (0.3 mg once daily) reduces the composite of all-cause death, aortic valve replacement, and hospitalization for heart failure in adults with asymptomatic moderate or severe aortic stenosis and preserved left ventricular ejection fraction (50% or higher). A total of 1,182 participants at 11 centers in the Republic of Korea will be randomized 1:1 to enavogliflozin or matching placebo, stratified by participating center and AS severity (moderate vs severe). Study treatment is given for 24 months, with follow-up visits at 2, 6, 12, 18, and 24 months and an end-of-treatment assessment at 25 months. Secondary outcomes include the individual components of the primary composite, cardiac death, echocardiographic AS severity, left ventricular mass, global longitudinal strain and ejection fraction, NT-proBNP, annual eGFR slope, and SGLT2 inhibitor-related adverse events. All clinical events are adjudicated by an independent clinical event adjudication committee, and safety is overseen by an independent data and safety monitoring board.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Design: Prospective, multicenter (11 sites, Republic of Korea), randomized (1:1), double-blind, placebo-controlled, parallel-group, superiority, investigator-initiated trial. Randomization is performed centrally through an interactive web response system (IWRS) managed by an independent organization, stratified by participating center and baseline AS severity (moderate vs severe).
Population: Adults aged 19 years or older with asymptomatic (NYHA class I) moderate or severe aortic stenosis, defined as aortic valve area less than 1.5 cm2, peak aortic jet velocity 3 m/s or higher, or mean pressure gradient 25 mmHg or higher, with left ventricular ejection fraction 50% or higher. Patients meeting ACC/AHA or ESC/EACTS indications for aortic valve intervention, with very severe AS (peak velocity 5 m/s or higher or mean gradient 50 mmHg or higher), severe concomitant valve disease, eGFR below 30 mL/min/1.73 m2 or dialysis, type 1 diabetes, or SGLT2 inhibitor use within 3 months are excluded.
Intervention: Enavogliflozin 0.3 mg orally once daily or matching placebo for 24 months, on top of guideline-directed medical therapy per ACC/AHA/SCAI or ESC/EACTS recommendations. Concomitant medications may be adjusted at the investigator's discretion.
Schedule: Screening (day -90 to 0), baseline/randomization (day 0), visits at day 60 +/- 30, 180 +/- 30, 360 +/- 30, 540 +/- 30, and 720 +/- 30, and end-of-treatment assessment at day 750 +/- 90. Transthoracic echocardiography is performed at baseline, 12, and 24 months (and at 6 and 18 months in participants with severe AS at baseline). Laboratory tests (including eGFR), NT-proBNP and cardiac troponin T, ECG, and chest radiography are obtained at prespecified visits. Medication adherence is assessed at every visit. Clinical events are ascertained at each follow-up visit and at the end-of-treatment assessment at 25 months, and thereafter vital status and clinical events are ascertained by visit, telephone contact, or medical-record review until the end of study.
Sample size: Assuming an annual primary-event rate of 6% in the placebo group, a hazard ratio of 0.65, 3 years of accrual, 2 additional years of follow-up, 5% dropout, two-sided alpha of 0.05, and 80% power, 591 participants per group (1,182 total) are required (time-to-event analysis, log-rank test).
Analysis: Primary analysis by intention to treat; per-protocol analysis (adherence 70% or higher, no SGLT2 inhibitor use in the placebo group) as sensitivity analysis. Time-to-event outcomes are analyzed by Kaplan-Meier estimates, log-rank test, and Cox proportional-hazards models; continuous echocardiographic and laboratory outcomes by independent t-test. Participants lost to follow-up are censored. Prespecified subgroups: AS severity (moderate vs severe), age (below 70 vs 70 years or older), diabetes, hypertension, chronic kidney disease, and baseline global longitudinal strain. An interim analysis is planned when approximately 50% of the expected data have been collected, reviewed by the independent data and safety monitoring board.
Oversight: All primary and secondary clinical events are adjudicated by an independent Clinical Event Adjudication Committee. An independent Data and Safety Monitoring Board reviews all serious adverse events. Serious adverse events are reported to the principal investigator within 72 hours and to each site IRB per local requirements. The trial is conducted in accordance with the Declaration of Helsinki, ICH-GCP, and Korean GCP (KGCP).
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 4
Kontakte und Standorte
Studienkontakt
- Name: GaHee Lee
- Telefonnummer: +82-2-2008-4135
- E-Mail: gahee2.lee@sbri.co.kr
Studieren Sie die Kontaktsicherung
- Name: Jinseon Heo
- E-Mail: jinseon.heo@sbri.co.kr
Studienorte
-
-
-
Busan, Südkorea
- Noch keine Rekrutierung
- Dong-A University Hospital
-
Hauptermittler:
- Kyung Hee Lim, MD, PhD
-
Changwon, Südkorea
- Noch keine Rekrutierung
- Samsung Changwon Hospital
-
Hauptermittler:
- Mirae Lee, MD, PhD
-
Cheonan, Südkorea
- Noch keine Rekrutierung
- Dankook University Hospital
-
Hauptermittler:
- Su Yeon Lee, MD, PhD
-
Gwangmyeong, Südkorea
- Noch keine Rekrutierung
- Chung-Ang University Gwangmyeong Hospital
-
Hauptermittler:
- Eun Jeong Cho, MD, PhD
-
Seongnam, Südkorea
- Noch keine Rekrutierung
- Seoul National University Bundang Hospital
-
Hauptermittler:
- Jiesuck Park, MD, PhD
-
Seoul, Südkorea, 06351
- Rekrutierung
- Samsung Medical Center
-
Kontakt:
- GaHee Lee
- Telefonnummer: +82-2-2008-4135
- E-Mail: gahee2.lee@sbri.co.kr
-
Hauptermittler:
- Sung-Ji Park, MD, PhD
-
Seoul, Südkorea
- Noch keine Rekrutierung
- Korea University Anam Hospital
-
Hauptermittler:
- So Ree Kim, MD, PhD
-
Seoul, Südkorea
- Noch keine Rekrutierung
- Kangbuk Samsung Hospital
-
Hauptermittler:
- Jiwon Kim, MD, PhD
-
Seoul, Südkorea
- Noch keine Rekrutierung
- Konkuk University Medical Center
-
Hauptermittler:
- Sung Hea Kim, MD, PhD
-
Seoul, Südkorea
- Noch keine Rekrutierung
- Asan Medical Center, University of Ulsan College of Medicine
-
Hauptermittler:
- Dae-Hee Kim, MD, PhD
-
Seoul, Südkorea
- Noch keine Rekrutierung
- Severance Hospital, Yonsei University College of Medicine
-
Hauptermittler:
- Chi Young Shim, MD, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Able to understand the study protocol and provide written informed consent
- Adults aged 19 years or older
- Moderate or asymptomatic severe aortic stenosis, defined as all of the following:
- Aortic valve area (AVA) less than 1.5 cm2, aortic valve peak velocity (Vmax) 3 m/s or higher, or aortic valve mean pressure gradient 25 mmHg or higher
- Left ventricular ejection fraction 50% or higher
- Asymptomatic, New York Heart Association (NYHA) functional class I
Exclusion Criteria:
- Left ventricular ejection fraction below 50%
- Indication for aortic valve intervention according to current ACC/AHA or ESC/EACTS guidelines
- Symptomatic severe aortic stenosis
- Severe stenosis or regurgitation of another valve, or concomitant severe aortic regurgitation
- Very severe aortic stenosis (aortic valve Vmax 5 m/s or higher, or mean pressure gradient 50 mmHg or higher)
- NYHA functional class II to IV
- Use of an SGLT2 inhibitor within the previous 3 months
- Known hypersensitivity to SGLT2 inhibitors
- Estimated glomerular filtration rate below 30 mL/min/1.73 m2, or on dialysis
- Type 1 diabetes mellitus
- Pregnancy or breastfeeding
- Liver disease with AST or ALT 2 or more times the upper limit of normal, or history of hepatic encephalopathy, esophageal varices, or portosystemic shunt
- Life expectancy below 2 years, or inability to comply with the study protocol
- Diabetic ketoacidosis
- Current use of medications that may affect efficacy assessment (DPP-4 inhibitors, vitamin K, calcium supplements)
- Sexually active women of childbearing potential who do not agree to use adequate contraception during the study
- Participation in another clinical trial within the previous 1 month or 5 half-lives of the investigational product
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Enavogliflozin
Enavogliflozin 0.3 mg film-coated tablet orally once daily for 24 months, in addition to guideline-directed medical therapy. |
Sodium-glucose cotransporter-2 inhibitor, 0.3 mg film-coated tablet, taken orally once daily for 24 months.
Andere Namen:
|
|
Placebo-Komparator: Placebo
Matching placebo tablet (identical in appearance) orally once daily for 24 months, in addition to guideline-directed medical therapy. |
Matching placebo tablet identical in appearance to enavogliflozin, taken orally once daily for 24 months. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Composite of all-cause death, aortic valve replacement, or hospitalization for heart failure
Zeitfenster: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to first occurrence of any component of the composite: all-cause death; surgical or transcatheter aortic valve replacement; or hospitalization for heart failure, defined as presentation to an acute care facility requiring an overnight stay with symptoms and signs of heart failure and treatment with intravenous diuretics, vasodilators, or inotropes, mechanical fluid removal, intra-aortic balloon pump, or initiation/doubling of oral diuretics. All events are adjudicated by an independent clinical event adjudication committee. |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
All-cause death
Zeitfenster: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to death from any cause after randomization. |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
|
Aortic valve replacement
Zeitfenster: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to first surgical or transcatheter aortic valve replacement after randomization. |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
|
Hospitalization for heart failure
Zeitfenster: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to first adjudicated hospitalization for heart failure after randomization (presentation to an acute care facility requiring an overnight stay with symptoms and signs of heart failure and treatment with intravenous diuretics, vasodilators, or inotropes, mechanical fluid removal, intra-aortic balloon pump, or initiation/doubling of oral diuretics). |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
|
Cardiac death
Zeitfenster: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to adjudicated cardiovascular death, including sudden cardiac death, death due to acute myocardial infarction, heart failure or cardiogenic shock, other cardiovascular causes, or death of unknown cause without an undisputed non-cardiac cause. |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
|
Change from baseline in aortic valve peak velocity
Zeitfenster: Baseline, 12 months, and 24 months
|
Change in peak aortic jet velocity (m/s) measured by transthoracic echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in mean transaortic pressure gradient
Zeitfenster: Baseline, 12 months, and 24 months
|
Change in mean transaortic pressure gradient (mmHg) measured by transthoracic echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in aortic valve area
Zeitfenster: Baseline, 12 months, and 24 months
|
Change in aortic valve area (cm2) calculated by the continuity equation on transthoracic echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in dimensionless index (velocity ratio)
Zeitfenster: Baseline, 12 months, and 24 months
|
Change in the dimensionless index (velocity ratio), defined as the ratio of left ventricular outflow tract to transaortic velocity (or velocity-time integral), measured by transthoracic echocardiography; unitless. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in left ventricular mass
Zeitfenster: Baseline, 12 months, and 24 months
|
Change in echocardiographic left ventricular mass (g). |
Baseline, 12 months, and 24 months
|
|
Change from baseline in left ventricular global longitudinal strain
Zeitfenster: Baseline, 12 months, and 24 months
|
Change in left ventricular global longitudinal strain (%) by speckle-tracking echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in left ventricular ejection fraction
Zeitfenster: Baseline, 12 months, and 24 months
|
Change in left ventricular ejection fraction (%) by transthoracic echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in NT-proBNP
Zeitfenster: Baseline, 12 months, and 24 months
|
Change in plasma N-terminal pro-B-type natriuretic peptide concentration (pg/mL). |
Baseline, 12 months, and 24 months
|
|
Annual eGFR slope
Zeitfenster: From baseline through 24 months
|
Mean slope of change in estimated glomerular filtration rate (CKD-EPI equation), expressed as mL/min/1.73 m2 per year. |
From baseline through 24 months
|
|
Number of participants with at least one adverse event of special interest related to SGLT2 inhibition (safety)
Zeitfenster: From first dose of study drug through 7 days after the last dose (up to approximately 25 months)
|
Number of participants experiencing one or more prespecified adverse events of special interest, reported as a single count per arm. Adverse events of special interest are: confirmed hypoglycemia (plasma glucose 70 mg/dL [3.9 mmol/L] or lower, or an event requiring assistance), urinary tract infection, genital infection, volume depletion, and acute kidney injury by KDIGO criteria. |
From first dose of study drug through 7 days after the last dose (up to approximately 25 months)
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Sung-Ji Park, MD, PhD, Samsung Medical Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2025-07-028
- KCT0012093 (Registrierungskennung: Clinical Research Information Service (CRIS), Republic of Korea)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Individual participant data will not be shared outside the study group because the informed consent and institutional policy do not permit external release of participant-level data. Aggregate results will be published in a peer-reviewed journal and reported to ClinicalTrials.gov.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .